Beyond the Biopsy: Creatv Bio Previews New Cancer Test at ASCO

MONMOUTH JUNCTION, NJ – May 05, 2026 – Diagnostic firm Creatv Bio is set to take the stage at one of the world's top oncology conferences, unveiling new data that highlights the potential of its advanced liquid biopsy technology. The company announced it will present five clinical data abstracts at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its LifeTracDx® blood test in collaboration with pharmaceutical partners BriaCell and CytoDyn.

The presentations will detail the test's utility in monitoring patients with advanced metastatic breast and colorectal cancers, offering a glimpse into a future where a simple blood draw could provide deep insights into a patient's disease progression and response to therapy.

A New Frontier in Cancer Detection

For decades, the standard for cancer diagnosis has been the tissue biopsy, an invasive procedure to remove a piece of a tumor for analysis. The rise of liquid biopsies—tests that detect cancer signals in blood—promises a less invasive, more dynamic way to monitor the disease. Creatv Bio is carving out a unique niche in this competitive space with its LifeTracDx® system.

Unlike many competitors that focus on analyzing fragments of circulating tumor DNA (ctDNA), Creatv Bio's technology uses proprietary CellSieve microfilters to isolate and analyze whole cells from a blood sample. This approach led the company's scientists to identify a unique biomarker: Cancer-Associated Macrophage-Like cells (CAMLs). According to the company's research, these cells are present in patients with cancer and contain intact, unfragmented tumor DNA. This distinction is critical, as intact DNA can potentially provide a more complete and accurate genomic picture of a tumor, aiding in the development of highly targeted treatments.

Despite its promise, the LifeTracDx® test is currently designated for "research and investigational use only." This status means it has not yet completed the rigorous regulatory reviews required by agencies like the U.S. Food and Drug Administration (FDA) for use in clinical diagnosis or treatment decisions. The path to full clinical approval for any diagnostic is long and requires extensive validation, but the data being presented at ASCO marks a significant step in gathering the necessary evidence.

Strategic Alliances Driving Clinical Validation

Creatv Bio's strategy hinges on deep collaboration with pharmaceutical companies, embedding its diagnostic technology directly into their clinical trials. This symbiotic relationship allows drug developers to better understand how their therapies are working while providing Creatv Bio with crucial data to validate its test.

The upcoming ASCO presentations are a direct result of these partnerships. A key poster presentation will feature an ongoing analysis from the Bria-ABC Phase 3 trial, a late-stage study run by immuno-oncology firm BriaCell for patients with advanced metastatic breast cancer. In the trial, LifeTracDx® is being used to monitor blood-based biomarkers as potential early predictors of progression-free survival. The inclusion in a Phase 3 trial is a significant vote of confidence, suggesting the technology is robust enough to be evaluated alongside a therapeutic seeking final approval.

Further collaborations with BriaCell, detailed in two other abstracts, explore using the test to monitor PD-L1 expression on circulating cells—a key biomarker for predicting response to immunotherapy—and to stratify patients by their risk of progression before starting systemic therapy.

Similarly, Creatv Bio is working with CytoDyn, a biotechnology company developing the drug leronlimab. Abstracts from this partnership will cover studies in metastatic triple-negative breast cancer and refractory metastatic colorectal cancer. In these trials, LifeTracDx® serves as an exploratory tool to identify biomarkers that could help predict patient outcomes and optimize treatment regimens.

ASCO Spotlight: A Glimpse into Patient Monitoring's Future

The ASCO Annual Meeting is the premier global stage for unveiling cancer research, where data presented can influence clinical practice for years to come. For a company like Creatv Bio, presenting at ASCO provides invaluable visibility and peer review from over 40,000 oncology professionals.

The abstracts offer a window into the next evolution of personalized medicine. The data on predicting progression-free survival in breast cancer, for example, could one day help oncologists make faster decisions about whether to continue or change a patient's treatment plan, without waiting months for imaging scans to show tumor growth or shrinkage. Monitoring PD-L1 expression through a blood test could also simplify the process of matching patients to powerful but costly checkpoint inhibitor immunotherapies.

This move toward dynamic, real-time monitoring reflects a major trend in oncology. Instead of relying on static snapshots from periodic tissue biopsies, liquid biopsies like LifeTracDx® offer the potential for continuous surveillance, allowing clinicians to adapt to a cancer's evolution in near real-time.

Navigating a Crowded and Competitive Field

Creatv Bio enters a liquid biopsy market that is both rapidly growing and fiercely competitive. The global market is projected to exceed $27 billion by 2035, attracting major players and significant investment. Industry leaders like Guardant Health and Exact Sciences already have FDA-approved tests on the market—Guardant360 for genomic profiling and Guardant Shield for colorectal cancer screening, and Cologuard for at-home screening, respectively.

Against these established giants, Creatv Bio's unique focus on CAMLs and whole-cell analysis is its primary differentiator. However, its investigational status places it at an earlier stage of commercialization. The company appears to be playing a strategic long game, focusing on diagnostic and monitoring applications rather than the highly competitive and even more stringently regulated early screening market. By proving its test's value as a companion or complementary diagnostic within pharmaceutical trials, Creatv Bio is building a strong foundation of clinical utility data.

While the LifeTracDx® test is not yet a tool in the hands of community oncologists, the research being unveiled in Chicago represents a critical milestone. The findings from collaborations with BriaCell and CytoDyn demonstrate the technology's potential to refine and personalize treatment for some of the most difficult-to-treat cancers, marking important progress on the long road from the research lab to the patient's bedside.